title: Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.
abstract: Hydroxyurea (HU) has traditionally been the first-line treatment for patients with polycythemia vera (PV) or essential thrombocythemia (ET) at high risk for vascular complications. However, approximately 20-25% of patients develop resistance or intolerance to HU and must be treated with second-line therapies. Resistance is associated with disease transformation and reduced survival. However, given the dearth of large-scale controlled clinical trials in this patient population, there is no clear consensus on how to best treat patients who develop resistance or intolerance to HU. Herein, we review current literature on treatment options for patients with HU-refractory/resistant PV or ET and provide recommendations for treating these patients.
authors: Department of Hematology, University Medical Center Ljubljana , Ljubljana , Slovenia.
authors: Matjaz
authors: M
authors: Sever
authors: Kate J
authors: KJ
authors: Newberry
authors: Srdan
authors: S
authors: Verstovsek
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002066:Busulfan / Q000627:therapeutic use; D019468:Disease Management; D004351:Drug Resistance; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000627:therapeutic use; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors; D010885:Pipobroman / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011087:Polycythemia Vera / Q000175:diagnosis / Q000628:therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D013920:Thrombocythemia, Essential / Q000175:diagnosis / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors; D016898:Interferon-alpha; D010975:Platelet Aggregation Inhibitors; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D010885:Pipobroman; D053614:Janus Kinase 2; D002066:Busulfan; C021139:anagrelide; D006918:Hydroxyurea
keywords: Polycythemia vera; essential thrombocythemia; hydroxyurea